Sana shelves its in vivo Car-T
The once-hyped group’s most advanced hope is an allogeneic CD19 Car-T, where competition is fierce.
Approval milestones – Hutchmed, SpringWorks, Crispr and Ionis eye firsts
A work-stretched US FDA has several key approval application still to review by the end of 2023.
Off-the-shelf Car-T from Caribou does enough at six months
Curiously, however, higher dosing does not seem to be the answer to the company’s relapse problem.
